EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Soluble B‐cell maturation antigen in multiple myeloma

Bruno Almeida Costa iD, Ricardo J Ortiz iD, Alexander M Lesokhin iD, Joshua Richter iD

American Journal of Hematology · 2024-04 · 99 (4) · 727-738

DOI: 10.1002/ajh.27225 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 25.01.2024. Verfasst von Bruno Almeida Costa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B‐cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody‐drug conjugates, bispecific antibodies, and chimeric antigen receptor T‐cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma‐secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme‐linked immunosorbent assays, as well as through mass spectrometry‐based proteomics. Besides its short serum half‐life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti‐myeloma therapies. In short, sBCMA might be the “Swiss army knife” of MM laboratory testing, but is it ready for prime time?

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificHumansB-Cell Maturation AntigenImmunotherapy, AdoptiveAmyloid Precursor Protein Secretases

Substanzen

B-Cell Maturation AntigenAntibodies, BispecificAmyloid Precursor Protein Secretases

Autor:innen und Institutionen

  • Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Medicine, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer, New York, New York, USA.
  • Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Bruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, Joshua Richter

Förderung

  • American Society of Hematology

Zitieren

APA

Costa, B. A., Ortiz, R. J., Lesokhin, A. M., & Richter, J. (2024). Soluble B‐cell maturation antigen in multiple myeloma. American Journal of Hematology, 99(4), 727-738. https://doi.org/10.1002/ajh.27225

Vancouver

Costa BA, Ortiz RJ, Lesokhin AM, Richter J. Soluble B‐cell maturation antigen in multiple myeloma. American Journal of Hematology. 2024;99(4):727-738. doi:10.1002/ajh.27225

BibTeX
@article{Costa2024,
  author = {Costa, Bruno Almeida and Ortiz, Ricardo J and Lesokhin, Alexander M and Richter, Joshua},
  title = {Soluble B‐cell maturation antigen in multiple myeloma},
  journal = {American Journal of Hematology},
  year = {2024},
  volume = {99},
  number = {4},
  pages = {727--738},
  doi = {10.1002/ajh.27225}
}
Kostenlos starten →